Kadmon Holdings, Inc.:
Announced pos. primary analysis results (May 2020) in pivotal trial of ROCK inhibitor-KD025 (Belumosudil) in cGVHD pts receiving 2+ prior therapy lines; ORRs of 73% and 74% in 200mg QD and 200mg BID arms, respectively. Belumosudil is being reviewed under Real-Time Oncology Review (RTOR) Pilot Program by the FDA; NDA submission exp Q4 2020. Enrolling pts in Ph 2 trial (sys. sclerosis).
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Middle Atlantic
Clinical Stage
Phase III
Disease Space
Autoimmune, Fibrosis, Immunotherapy, Oncology
Industry
Biotechnology, Pharmaceuticals
Listing
Public, USA
Market Cap
500MM - 1B
Website:
Profiles:
Address:
450 East 29th Street
New York, NY 10016
United States
New York, NY 10016
United States
Presentation:
Company Participants at Solebury Trout CEO & Investor Ski Conference 2020
- Ellen Cavaleri, Director, Investor Relations
- Harlan W. Waksal, MD, President and CEO
- Steve Meehan, CFO
More info:
My account:
Lead Programs
KD025
| Indication | Phase |
|---|---|
| Chronic Graft-Versus-Host Disease | 2 |
| Systemic Sclerosis | 2 |
| Idiopathic Pulmonary Fibrosis | 2 |
KD034
| Indication | Phase |
|---|---|
| Wilson’s Disease | 3 |
Top 10 Holders of Kadmon Holdings Inc Warrant 2017-28.09.22 On Kadmon Hldngs
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| The Vanguard Group, Inc. | 0.00 | 0 | 0.00 | Funds | 8/31/20 |
Top 10 Holders of Kadmon Holdings, Inc.
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | 12.12 | 15,711,334 | 59.70 | 13F | 6/30/20 |
| Consonance Capital Management LP | 12.12 | 15,710,548 | 59.70 | 13F | 6/30/20 |
| The Vanguard Group, Inc. | 6.03 | 7,832,631 | 29.76 | Funds | 8/31/20 |
| Vanguard Group, Inc. (Subfiler) | 5.89 | 7,630,552 | 29.00 | 13F | 6/30/20 |
| Third Point LLC | 5.86 | 7,601,115 | 28.88 | 13F | 6/30/20 |
| State Street Corp. | 5.59 | 7,247,647 | 27.54 | 13F | 6/30/20 |
| Avidity Partners Management LP | 4.96 | 6,426,700 | 24.42 | 13F | 6/30/20 |
| Boxer Capital LLC | 4.79 | 6,205,882 | 23.58 | 13F | 6/30/20 |
| Woodline Partners LP | 4.65 | 6,030,531 | 22.92 | 13F | 6/30/20 |
| Citadel LP | 4.37 | 5,663,222 | 21.52 | 13F | 6/30/20 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.